Drugs & Targets FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements December 06, 2019Vol.45 No.45
Drugs & Targets China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication December 06, 2019Vol.45 No.45
Drugs & Targets Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication December 06, 2019Vol.45 No.45
Clinical Roundup Study finds wide county-level variation in rates of surgery for early-stage lung cancer December 06, 2019Vol.45 No.45
Clinical Roundup Tecentriq + Avastin combination demonstrates improvement in OS, PFS in HCC December 06, 2019Vol.45 No.45
Clinical Roundup Alunbrig demonstrates reduced risk of death, disease progression in ALK+ NSCLC December 06, 2019Vol.45 No.45
Clinical Roundup Experimental targeted therapy may be better for repeat kidney cancer patients than FDA-approved counterpart, study finds December 06, 2019Vol.45 No.45
Clinical Roundup Duke researchers develop technique to visually depict how cancer cells grow and spread in colon tissue December 06, 2019Vol.45 No.45
Funding Opportunities ACS and Flatiron Health launch real-world data impact award December 06, 2019Vol.45 No.45
